Genetics

Recent advances in genetic analysis are reshaping how we search for new treatments for multiple sclerosis (MS). In this post, we explore a groundbreaking study that analyzed hundreds of plasma and cerebrospinal fluid proteins using Mendelian randomization to uncover which ones truly influence MS risk. The research highlighted five promising proteins—FCRL3, TYMP, AHSG, MMEL1, and SLAMF7—that could serve as future drug targets, some even connected to pathways used by today’s MS therapies. With progressive MS still lacking effective options, these findings open an exciting door toward more precise, genetically informed treatments.